Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN315461 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Activating Transcription Factor 3 (ATF3) (AA 100-150) antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Epitope
- AA 100-150
- Vial size
- 0.1 mL
- Storage
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
- Handling
- Avoid freeze-thaw cycles
Submitted references Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Hu J, Dang N, Menu E, De Bruyne E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K
Blood 2012 Jan 19;119(3):826-37
Blood 2012 Jan 19;119(3):826-37
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra JE
Journal of medicinal chemistry 2011 Nov 24;54(22):7751-8
Journal of medicinal chemistry 2011 Nov 24;54(22):7751-8
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
